We offer an unrivalled client experience, with a hand’s on, expert approach in everything we do. The owners of the business are the point of contact for clients and develop the strategies necessary to deliver sustainable value to companies and their shareholders.
There are close to 2,300 companies listed on the ASX, with a diminishing pool of analysts, brokers, media and specialist investors to target at the small to mid-capitalisation (‘cap’) company end of the market. According to the ASX, approximately 37% of all companies on the exchange have one or more analyst who provides research coverage. In other words, more than 60% of public companies have no research coverage whatsoever to drive shareholder and non-shareholder interest/awareness and to achieve an appropriate valuation. These market inefficiencies provide an opportunity for Nemean clients to pro-actively capitalise on.
At Nemean, we specialise in delivering value-added services across the life sciences, medical devices, healthcare and emerging companies sectors.
We specialise in assisting Boards and management across small to mid-cap companies in meeting their strategic and corporate objectives.
Nemean provides deeply analytical, incisive and credible equity research devoid of traditional banking conflicts to clients.
Our advisory service assists clients to improve performance, grow shareholder value and appropriately manage risks.
Partner with Nemean. Get in touch to find out how to get started.